English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Breast cancer (BC) is the second incidence and the fifth leading cause to cancer death in the worldwide. In developing countries, the number of BC cases is still increased annually accompanied with the changes of lifestyle and screening programs. Nevertheless, the majority of BC patients are diagnosed as non-curative stage. Thereby, systemic therapy always plays an important role in BC treatment strategies. Among chemotherapy regimens, the combination of anthracyclin and taxane as an adjuvant treatment has been proven the efficacy and safety in terms of prolonging survival. In this study, we evaluated the incidence of chemotherapy-induced amenorrhea in breast cancer patients who were treated with adjuvant anthracycline and taxane-based chemotherapy.

oalib

Incidence of Chemotherapy-Induced Amenorrhea in Premenopausal Patients with Breast Cancer Following Adjuvant Chemotherapy with Anthracycline and Taxane